aud 0.2150 <%= Resources.Global.txtDown %>
Updated 30/06/2017
Change % -2.27% Stock price decreasing
Change -0.005 Stock price decreasing
Volume 690,733
High AUD 0.2200
Low AUD 0.2150
Open AUD 0.2200
Prev close AUD 0.2200
# of shares -
Market cap -

Market closed
Acrux FPO
Market is closed, opens at 01:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  0.22 0.0% Stock price unchanged 0.0% Stock price unchanged 0.0% Stock price unchanged 0.0% Stock price unchanged -23.2% Stock price decreasing
Powered by TradingView

Company profile

Acrux is an Australian drug delivery specialist focused on developing transdermal pharmaceutical products. It uses proprietary transdermal technology to develop new formulations of established drugs, bringing clinical and product life cycle management benefits. Former licensee partner Eli Lilly marketed lead product Axiron for low testosterone levels in a number of countries, including the United States. Other marketed products include Evamist spray (for menopause-related symptoms) and Recuvyra (for postoperative pain management in dogs).

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
21 April 2018 03:04:11
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB3 - 2018-04-21 04:04:11 - 2018-04-21 03:04:11 - 1000 - Website: OKAY